WO2007084582A2 - Drug delivery treatment device - Google Patents
Drug delivery treatment device Download PDFInfo
- Publication number
- WO2007084582A2 WO2007084582A2 PCT/US2007/001269 US2007001269W WO2007084582A2 WO 2007084582 A2 WO2007084582 A2 WO 2007084582A2 US 2007001269 W US2007001269 W US 2007001269W WO 2007084582 A2 WO2007084582 A2 WO 2007084582A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eye
- drug
- elongate member
- suprachoroidal space
- elongate
- Prior art date
Links
- 0 *CC1*2NCC12 Chemical compound *CC1*2NCC12 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Prostheses (AREA)
- Pulmonology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Disclosed are devices and methods for treatment of eye disease. The suprachoroidal space is used as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.
Description
DRUG DELIVERY TREATMENT DEVICE
Related Applications
Benefit of priority under 35 U.S.C. § 119(e) is claimed to U.S. Provisional Application Serial No 60/759,835, filed January 17, 2006, entitled 11 GLAUCOMA TREATMENT DEVICE;" to U.S. Provisional Application Serial No 60/783,632, filed March 17, 2006, entitled " GLAUCOMA TREATMENT DEVICE"; and to U.S. Provisional Application Serial No. 60/824,552, filed September 5, 2006, entitled "GLAUCOMA TREATMENT DEVICE."
The subject matter of each of the above-noted provisional applications and international applications is incorporated by reference in its entirety by reference thereto.
BACKGROUND
This disclosure relates generally to methods and devices for use in treating various ocular diseases. Glaucoma is caused by a number of different eye diseases which can produce increased intraocular pressure (lOP) in the eye. The increased pressure is often caused by a backup of aqueous humour within the eye. Overtime, the increased pressure can cause damage to the optic nerve, which can lead to blindness.
One way to treat glaucoma is to implant a drainage device, or shunt, in the eye. The drainage device functions to drain aqueous humour from the anterior chamber and thereby reduce the intraocular pressure. The drainage device is typically implanted using to an invasive surgical procedure. Pursuant to one such procedure, a flap is surgically formed in the sclera. The
flap is folded back to form a small cavity and a shunt is inserted into the eye through the flap. Such a procedure can be quite traumatic for the patient.
The following references describe various devices and procedures for treating glaucoma: United States Patent 6,827,700 to Lynch, 6,666,841 to Bergheim, 6,508,779 to Suson, 6,544,208 to Ethier, 5,601 ,094 to Reiss, 6,102,045 to Nordquist, United States Patent Application 2002/0156413 to Williams, 2002/0143284 to Tu, 2003/0236483 to Ren, 2002/0193725 to Odrich, 2002/0165478 to Gharib, 2002/0133168 to Smedley, 2005/0107734, 2004/0260228 to Lynch, 2004/0102729 to Haffner, 2004/0015140 to Sheilds, 2004/0254521 to Simon, 2004/0225250 to Yablonski . The aforementioned references are all incorporated herein by reference in their entireties.
Current devices and procedures for treating glaucoma have disadvantages and in some cases only moderate success rates. The procedures are very traumatic to the eye and also require highly accurate surgical skills, such as to properly place the drainage device in a proper location. In addition, the devices that drain fluid from the anterior chamber to a subconjunctival bleb beneath a scleral flap, are prone to infection, and can occlude and cease working. This can require re-operation to remove the device and place another one, or can result in further surgeries. In addition, for agents delivered via direct injection, other complications result, and numerous office visits are required to keep a therapeutic dose resident in the eye. In view of the foregoing, there is a need for improved devices and methods for the treatment of a variety of ocular diseases.
SUMMARY
Disclosed are devices and methods for treatment of eye disease such as glaucoma. Using the devices and introduction and placement techniques of the present invention, it is possible to place a device using the suprachoroidal space as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir at some point along the device to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.
In addition, the devices of the present invention may be used to augment and assist delivery of drugs to the back of the eye either through injection into a port of the device, or by directing therapeutic agents placed by drops into the eye, but direction the flow of the aqueous containing the drop, into the suprachoroidal space and beyond, to various locations toward the back of the eye.
Placement of a suprachoroidal implant can also assist in delivering drugs to various locations within the eye, including to the back of the eye.
Injections to the back of the eye to treat a wide variety of systemic and ocular conditions such as inflammation, infection, cancerous growth, may be prevented or treated using the drug delivery devices of the present invention. More specifically, ocular conditions such as glaucoma, proliferative vitreoretinopathy, diabetic retinopathy, dry and wet AMD, uveitis, keratitis,
cytomegalovirus retinitis, cystoid macular edema, herpes simplex viral and adenoviral infections can be treated or prevented. In many cases, multiple injections are required, leading to degradation of the injection site, and numerous office visits, resulting in increased cost to the healthcare system as well as issues of compliance with patients.
In one aspect, there is disclosed a device for delivering an agent to the eye, comprising an elongate element adapted for at least partial placement in a suprachoroidal space of the eye, the elongate element having a proximal end and a distal end, wherein the proximal end is positioned at a first location of the eye and wherein the distal end extends to a location within a posterior segment of the eye, the elongate element adapted to deliver a drug into the eye.
In another aspect, there is disclosed a method of delivering drug into the eye, comprising: implanting an elongate element in the eye such that at least a portion of the elongate member is positioned within the suprachoroidal space of the eye, the elongate member adapted to deliver a drug into the eye; and inserting a drug into the elongate member such that the drug flows along the elongate member into the suprachoroidal space.
In another aspect, there is disclosed a method of delivering drug into the eye, comprising: forming an incision in the cornea of the eye; inserting an elongate member through the incision into the eye wherein the elongate member is adapted to transport a drug; passing the delivery device along a pathway through the scleral spur of the eye into the suprachoroidal space; and flowing drug along the delivery device into the suprachoroidal space.
In another aspect, there is disclosed a method of delivering drug into the eye, comprising: implanting an elongate element in the eye such that at least a portion of the elongate member is positioned within the suprachoroidal space of the eye, the elongate member adapted to deliver a drug into the eye; placing a drop of a treatment medium onto the surface of the eye; permitting the treatment medium to flow into the anterior chamber of the eye; and causing the treatment medium to flow into the elongate member such that the treatment medium flows along the elongate member into the suprachoroidal space.
Other features and advantages should be apparent from the following description of various embodiments, which illustrate, by way of example, the principles of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a cross-sectional, perspective view of a portion of the eye showing a drug delivery device positioned in the eye.
Figure 2A shows an exemplary embodiment of the drug delivery device.
Figure 2B shows another embodiment of the drug delivery device.
Figure 2C shows another embodiment of the drug delivery device.
Figure 2D shows another embodiment of the drug delivery device.
Figure 2E shows another embodiment of the drug delivery device.
Figure 2F shows another embodiment of the drug delivery device.
Figure 3 shows the drug delivery device mounted on a delivery device during deployment of the device.
Figure 4 shows various exemplary regions of the eye where a distal end of the drug delivery device can be located.
Figures 5A-5G show various exemplary regions of the eye where a proximal end of the drug delivery device can be located.
DETAILED DESCRIPTION
Figure 1 is a cross-sectional, perspective view of a portion of the eye showing the anterior and posterior chambers of the eye. A drug delivery device is positioned inside the eye such that a distal end is located in a location of the eye to which one or more drugs are to be delivered. In an exemplary embodiment, the drug delivery device is positioned in the eye such that one or more drugs can be delivered to the suprachoroidal space. Embodiments of the drug delivery device with various structural configurations are described in detail below.
Using the devices and introduction and placement techniques of the present invention, it is possible to place a device that uses the suprachoroidal space as a conduit within which to place a drug delivery device such as the device described herein. One such drug delivery device may be a wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate.
Figure 1 shows an exemplary drug delivery device 2910 extending from a point of entry at the scleral spur, and extending to the back of the eye.
At least a portion of the drug delivery device 2910 is positioned within and anchored within the suprachoroidal space and can have a profile that is configured to seal within the suprachoroidal space. Another portion of the drug delivery device 2910 is positioned in a different location of the eye.
One or more drug reservoir regions 2915 may be optionally formed within the suprachoroidal space for receipt of a drug. The drug reservoir region can be a space or volume within the suprachoroidal space into which a drug is inserted. A proximal end or proximal region 2918 of the drug delivery device 2910 can include a port that receives a drug for delivery into the suprachoroidal space, such as into the reservoir region 2915. With the body of the drug delivery device 2910 being anchored within the suprachoroidal space, the distal end and/or the proximal end of the device can be located at various locations relative to the eye to achieve a desired manner of drug delivery, as described below.
The drug delivery device 2910 can have a variety of structures. For example, as shown in Figure 2A, the drug delivery device 2910 can be an elongate member with an internal lumen for drug delivery. As shown in Figure 2B, the drug delivery device 2910 can include one or more retention features, such as prongs 2925, that anchor the drug delivery device in a fixed position within the eye. In another embodiment, shown in Figure 2C, the drug delivery device 2910 is an elongate member with an internal lumen 2927 and an anchor member, such as a flange 2930, located at the proximal end of the drug delivery device 2910. An injection port 2932 communicates with the internal lumen 2927 for injection of a drug.
Figure 2D shows another embodiment of a drug delivery device 2910 that comprises a wicking member without an internal lumen. The wicking member can be formed of a single strand of material or can be formed of a plurality of strands that are interconnected, such as in a twisted, braided, or woven fashion, and through or along which fluid can flow. The wicking member can be a tube that includes an internal lumen that is used to deliver the drug or therapeutic agent directly to the location of the distal end of the delivery device 2910. The wick member(s) do not necessarily include internal lumens, as flow through the wick member can occur via capillary action. In the case of a solid polymer wick, certain surface detents can provide flow lumens between the central body member and the tissue of the suprachoroidal space. The embodiment of Figure 2D includes a proximal anchor member, such as a flange 2930.
Any of the embodiments of the drug delivery device can include anchoring or retention members, such as fenestrations 2912 on the distal end of the device 2910 in Figure 2D. The fenestrations 2912 can be located at any location along the length of the device. Moreover, any of the embodiments can include one or more valve members that regulate fluid flow. The valve element can cause fluid to collect in a region of the device and then release the collected fluid such as upon a certain pressure threshold. In this manner, the a concentrated amount of drug can be delivered into the eye.
Figure 2E shows the drug delivery device 2910 as a wicking member without a flange. With reference to Figure 2F, the drug delivery device 2910 can include a proximal flange 2930 having an injection port that
communicates with a drug reservoir 2940. The reservoir can be filled with a drug or other therapeutic agent such that the drug wicks along the length of the drug delivery device. The reservoir can be re-filled with the drug as needed. The flange 2930 can be positioned at the scleral spur when the device is implanted. The reservoir 2940 is positioned adjacent a leaching body 2940 for drug delivery. A reservoir 2940 can also be located at or near the distal end of the device 2910.
In an embodiment, the drug delivery device 2910 is adapted to deliver drops placed on the surface of the eye to suprachoroidal space. This is described further detail below with reference to Figure 5E. The drug may be delivered to the back regions of the eye, such as regions rearward of the eye equator. One or more drops of a drug or therapeutic agent are placed on the surface of the eye where the drug mixes with the tear film. The tear film directs the drug into an entry port of the drug delivery device 2910. The entry port may be positioned, for example, within the anterior chamber. The drug then flow via the drug delivery device 2910 into the suprachoroidal space and potentially to the back regions of the eye. The drug may mix with aqueous humor as it flows into and along the drug delivery device 2910. In this manner, the drug delivery device 2910 is used to direct drops placed on the eye surface to the back of the eye such as to treat any of a variety of eye diseases.
In another embodiment, a punctal plug is used to deliver a drug to the tear film and into the anterior chamber where the drug intermingles with the aqueous humor. The drug delivery device 29210 then delivers the drug into
the suprachoroidal space and possibly to back regions of the eye. Pursuant to such an embodiment, one or more punctal plugs are placed in the eye, such as in the corners of the eye. The punctal plugs can be placed in various regions of the eye, such as in the lower two puncta and/or in the upper puncta. One or more drops of a drug or therapeutic agent are then placed onto the eye such that the drug flows into the anterior chamber via the puntal plugs. The drug then flows into an entry port in the drug delivery device 2910 and flows into the suprachoroidal space via the drug delivery device 2910. International Patent Publication WO 06/014434 to Lazar describes exemplary devices and methods for drug delivery through punctal plugs. That publication is incorporated herein by reference in its entirety.
A wide variety of systemic and ocular conditions such as inflammation, infection, cancerous growth, may be prevented or treated using the drug delivery devices of the present invention. More specifically, ocular conditions such as glaucoma, proliferative vitreoretinopathy, diabetic retinopathy, uveitis, keratitis, cytomegalovirus retinitis, cystoid macular edema, herpes simplex viral and adenoviral infections can be treated or prevented.
Depending on the dose required, and the delivery profile of the agent delivered, it may be advantageous for the drug delivery device to extend from the initial dissection plane at the point of the scleral spur, within the suprachoroidal space to the posterior segment of the eye, or any location therebetween. The geometry of the drug delivery device may assist in the ability to prolong or control various dosing regimes. For example, a longer delivery device may equate to a longer dosing potential, and similarly a larger
diameter device may assist with this also. Because the drug delivery device of the present invention completely fills the suprachoroidal space, a "washout" effect may be minimized, thereby also assisting in the dosing. In addition, it may be advantageous to employ a sealant, to seal any communication between the anterior chamber and the newly dissected suprachoroidal space once the drug delivery device is placed. Products such as Tisseal® (Baxter Healthcare, Irvine, CA), fibrin glues, or small amounts of cyanoacrylate may be used for this purpose.
Alternatively, if delivery of a therapeutic agent of the present invention is desired in the anterior chamber, or within the sclera, tribecular meshwork, choroid or other structures in proximity to the suprachoroidal space, the entry point at which the delivery device accesses the suprachoroidal space may be varied, such that the distal end of the drug delivery device may be placed in the suprachoroidal space as a means for anchoring the device, and the proximal end (end nearest the outside of the eye) may be placed at the desired delivery location.
With reference to Figure 3, the drug delivery device 2910 can be mounted on an elongate delivery member 525 and can enter the suprachoroidal space at or near the scleral spur. In general, the drug delivery device is implanted using a delivery system by accessing the scleral spur to create a low profile dissection in the tissue plane between the choroid and the sclera. An incision can be formed in the cornea and the drug delivery device is inserted through the incision. The drug delivery device can pass along a pathway through the scleral spur of the eye into the suprachoroidal space.
The drug delivery device is then secured in the eye so that it provides communication between a drug delivery inlet and the suprachoroidal space.
The drug delivery device 2910 can be positioned within the suprachoroidal space or can have a length such that the distal end of the drug delivery device is positioned at any of a variety of points along the length of the suprachoroidal space, such as any point from the scleral spur to the back regions of the eye. Figure 4 shows various regions, D1-D6 where the distal end of the drug delivery device can be located. It should be appreciated that the regions are for purpose of example and do not limit where the distal end can be positioned.
The proximal end of the drug delivery device 2910 can be positioned at various locations relative to the eye, as shown in Figures 5A-5F. In Figure 5A, the proximal end of the drug delivery device 2910 is positioned at a location P1 , which is within the cornea C. In Figure 5B, the proximal end is positioned at a location P2, which is within the sclera S. In Figure 5C, the proximal end is positioned at a location P3, which is within the conjunctiva C. In Figure 5D, the proximal end is positioned at a location P4, which is within posterior chamber PC. In Figure 5E, the proximal end is positioned at a location P5, which is within the anterior chamber AC. In Figure 5F, the proximal end is positioned at a location P6, which is outside of the eye. Other locations for the proximal end of the drug delivery device are also possible. Moreover, the locations P1-P4 are merely exemplary and are intended to represent regions of the eye rather than exact locations. The drug delivery device can be removed from the eye after drug delivery is complete. The
drug delivery device can also be bioabsorbable so that it does not need to be removed.
With reference to Figure 5G, a container, such as a drop bottle 2970, is adapted to deliver one or more drops 2972 of a drug or therapeutic agent onto the surface of the eye. The tear film directs the drug into the anterior chamber, as represented schematically by the arrows 2976 in Figure 5G. The drug then flows into the entry port 2960 of the drug delivery device 2910, which guides the drug into the suprachoroidal space.
With respect to any of the embodiments of Figure 5A-5G, the proximal end of the drug delivery device 2910 can include a port 2960 that is adapted to receive a drug. The port 2960 can have various structural configurations and shapes. For example, the port 2960 can be funnel-shaped, flanged, or widened to facilitate entry of the drug into the delivery device. The port 2960 can also be made of a material that is adapted to absorb or otherwise attract the drug.
The following classes of drugs could be delivered using the devices of the present invention: anesthetics, analgesics, cell transport/mobility impending agents such as colchicine, vincristine, cytochalasin B and related compounds; antiglaucoma drugs including beta-blockers such as timolol, betaxolol, atenolol, and prostaglandin analogues such as bimatoprost, travoprost, latanoprost etc; carbonic anhydrase inhibitors such as acetazolamide, methazolamide, dichlorphenamide, diamox; and neuroprotectants such as nimodipine and related compounds. Additional examples include antibiotics such as tetracycline, chlortetracycline, bacitracin,
neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin; antibacterials such as sulfonamides, sulfacetamide, sulfamethizole and sulfisoxazole; anti-fungal agents such as fluconazole, nitrofurazone, amphotericine B, ketoconazole, and related compounds; anti-viral agents such as trifluorothymidine, acyclovir, ganciclovir, DDI, AZT, foscamet, vidarabine, trifluorσuridine, idoxuridine, ribavirin, protease inhibitors and anti-cytomegalovirus agents; antiallergenics such as methapyriline; chlorpheniramine, pyrilamine and prophenpyridamine; antiinflammatories such as hydrocortisone, dexamethasone, fluocinolone, prednisone, prednisolone, methylprednisolone, fluorometholone, betamethasone and triamcinolone; decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; miotics and anti-cholinesterases such as pilocarpine, carbachol, di-isopropyl fluorophosphate, phospholine iodine, and demecarium bromide; mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine; sympathomimetics such as epinephrine and vasoconstrictors and vasodilators; Ranibizumab, Bevacizamab, and Triamcinolone.
Non-steroidal antiinflammatories (NSAIDs) may also be delivered, such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, PA; indomethacin; mefenamic acid), COX-2 inhibitors (CELEBREX® from Pharmacia Corp., Peapack, NJ; COX-1 inhibitors), including a prodrug Nepafenac®; immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, , Collegeville,
PA), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Anticlotting agents such as heparin, antifibrinogen, fibrinolysin, anti clotting activase, etc., can also be delivered.
Antidiabetic agents that may be delivered using the present devices include acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, tolbutamide, insulin, aldose reductase inhibitors, etc. Some examples of anti-cancer agents include 5-fluorouracil, adriamycin, asparaginase, azacitidine, azathioprine, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, estramustine, etoposide, etretinate, filgrastin, floxuridine, fludarabine, fluorouracil, fluoxymesterone, flutamide, goserelin, hydroxyurea, ffosfamide, leuprolide, levamisole, lomustine, nitrogen mustard, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, pentostatiπ, pipobroman, plicamyciπ, procarbazine, sargramostin, streptozocin, tamoxifen, taxol, teniposide, thioguanine, uracil mustard, vinblastine, vincristine and vindesine.
Hormones, peptides, nucleic acids, saccharides, lipids, glycolipids, glycoproteins, and other macromolecules can be delivered using the present devices. Examples include: endocrine hormones such as pituitary, insulin, insulin-related growth factor, thyroid, growth hormones; heat shock proteins; immunological response modifiers such as muramyl dipeptide, cyclosporins, interferons (including α, β, and Y interferons), interleukin-2, cytokines, FK506 (an epoxy-pyrido-oxaazcyclotricosine-tetrone, also known as Tacrolimus),
tumor necrosis factor, pentostatin, thymopentin, transforming factor beta2, erythropoetin; antineogenesis proteins (e.g., anit VEGF, Interferons), among others and anticlotting agents including anticlotting activase. Further examples of macromolecules that can be delivered include monoclonal antibodies, brain nerve growth factor (BNGF), celiary nerve growth factor (CNGF), vascular endothelial growth factor (VEGF), and monoclonal antibodies directed against such growth factors. Additional examples of immuπomodulators include tumor necrosis factor inhibitors such as thalidomide.
In addition, nucleic acids can also be delivered wherein the nucleic acid may be expressed to produce a protein that may have a variety of pharmacological, physiological or immunological activities. Thus, the above list of drugs is not meant to be exhaustive. A wide variety of drugs or agents may be used in the present invention, without restriction on molecular weight, etc.
Additional examples of beneficial drugs that may be employed in the present invention and the specific conditions to be treated or prevented are disclosed in Remington, supra; The Pharmacological Basis of Therapeutics, by Goodman and Gilman, 19th edition, published by the MacMillan Company, London; and The Merck Index, 13th Edition, 1998, published by Merck & Co., Rahway, NJ., and United States Patent 6,331,313 to Wong, which is previously expressly incorporated herein by reference, including the above text.
Although embodiments of various methods and devices are described herein in detail with reference to certain versions, it should be appreciated that other versions, embodiments, methods of use, and combinations thereof are also possible. Therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
Claims
1. A device for delivering an agent to the eye, comprising: an elongate element adapted for at least partial placement in a suprachoroidal space of the eye, the elongate element having a proximal end and a distal end, wherein the proximal end is positioned at a first location of the eye and wherein the distal end extends to a location within a posterior segment of the eye, the elongate element adapted to deliver a drug into the eye.
2. A device as in claim 1 , wherein the first locationis located at one of the cornea, sclera, conjunctiva, anterior chamber, or posterior chamber.
3. A device as in claim 2, wherein the distal end extends to the suprachoroidal space.
4. A device as in claim 1 , wherein the elongate element has an internal lumen through which the drug can flow into the suprachoroidal space.
5. A device as in claim 1 , wherein the elongate element is a wick.
6. A device as in claim 1 , wherein the wick through which drug flows pursuant to capillary action.
7. A device as in claim 1 , wherein the distal end is positioned entirely in the suprachoroidal space when the device is positioned in the eye.
8. A device as in claim 1 , wherein the device extends through the scleral spur when the device is positioned in the eye.
9. A device as in claim 1 , further comprising an anchor on the elongate member, the anchor adapted to anchor the elongate member in a fixed position within the eye.
10. A device as in claim 1 , further comprising a flange positioned on a proximal end of the elongate member.
11. A device as in claim 1 , wherein a proximal region of the elongate member includes an internal reservoir that can be filled with a drug.
12. A device as in claim 1, wherein the elongate element includes an anchor adapted to retain the elongate element in a fixed position in the eye.
13. A device as in claim 1 , wherein the elongate element includes a port adapted to receive the drug.
14. A device as in claim 13, wherein the port is on a proximal end of the elongate element.
15. A device as in claim 1 , wherein the elongate element includes an internal reservoir for collecting the drug.
16. A device as in claim 15, wherein the reservoir is at a distal region of the elongate element.
17. A device as in claim 1 , further comprising a valve that regulates fluid flow along the elongate element.
18. A device as in claim 1, wherein at least a portion of the implant is hooked.
19. A method of delivering drug into the eye, comprising: implanting an elongate element in the eye such that at least a portion of the elongate member is positioned within the suprachoroidal space of the eye, the elongate member adapted to deliver a drug into the eye; and inserting a drug Into the elongate member such that the drug flows along the elongate member into the suprachoroidal space.
20. A method as in claim 19, wherein the drug flows through an internal lumen in the elongate member.
21. A method as in claim 19, wherein the drug flows through along the elongate member pursuant to capillary action.
22. A method as in claim 19, wherein a distal region of the elongate member is positioned entirely in the suprachoroidal space.
23. A method as in claim 19, wherein a proximal end of the elongate member is positioned in one of the cornea, sclera, conjunctiva, anterior chamber, or posterior chamber of the eye.
24. A method as in claim 19, further comprising forming a reservoir in the suprachoroidal space for receipt of a drug.
25. A method as in claim 24, wherein a distal end of the elongate member is positioned in the reservoir.
26. A method of delivering drug into the eye, comprising: forming an incision in the cornea of the eye; inserting an elongate member through the incision into the eye wherein the elongate member is adapted to transport a drug; passing the delivery device along a pathway through the scleral spur of the eye into the suprachoroidal space; and flowing drug along the delivery device into the suprachoroidal space.
27. A method as in claim 26, wherein the drug flows through an internal lumen in the elongate member.
28. A method as in claim 26, wherein the drug flows through along the elongate member pursuant to capillary action.
29. A method as in claim 26, wherein a proximal end of the elongate member is positioned in one of the cornea, sclera, conjunctiva, anterior chamber, or posterior chamber of the eye.
30. A method as in claim 26, further comprising forming a reservoir in the suprachoroidal space for receipt of a drug.
31. A method as in claim 30, wherein a distal end of the elongate member is positioned in the reservoir.
32. A method of delivering drug into the eye, comprising: implanting an elongate element in the eye such that at least a portion of the elongate member is positioned within the suprachoroidal space of the eye, the elongate member adapted to deliver a drug into the eye; placing a drop of a treatment medium onto the surface of the eye; permitting the treatment medium to flow into the anterior chamber of the eye; and causing the treatment medium to flow into the elongate member such that the treatment medium flows along the elongate member into the suprachoroidal space.
33. A method as in claim 32, wherein the treatment medium flows into the anterior chamber via tear film.
34. A method as in claim 32, wherein the treatment medium flows into the anteior chamber via a punctal plug.
35. A method as in claim 32, wherein the treatment medium flows into a region of the suprachoroidal space at the back of the eye.
36. A method as in claim 32, wherein the treatment medium mixes with aqueous humor as the treatment medium flows into the anterior chamber.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2637602A CA2637602C (en) | 2006-01-17 | 2007-01-17 | Drug delivery treatment device |
JP2008551364A JP5388582B2 (en) | 2006-01-17 | 2007-01-17 | Drug administration device |
ES07718113.9T ES2653845T3 (en) | 2006-01-17 | 2007-01-17 | Drug administration treatment device |
EP07718113.9A EP1978892B1 (en) | 2006-01-17 | 2007-01-17 | Drug delivery treatment device |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75983506P | 2006-01-17 | 2006-01-17 | |
US60/759,835 | 2006-01-17 | ||
US78363206P | 2006-03-17 | 2006-03-17 | |
US60/783,632 | 2006-03-17 | ||
US82455206P | 2006-09-05 | 2006-09-05 | |
US60/824,552 | 2006-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007084582A2 true WO2007084582A2 (en) | 2007-07-26 |
WO2007084582A3 WO2007084582A3 (en) | 2007-12-21 |
Family
ID=38288219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/001269 WO2007084582A2 (en) | 2006-01-17 | 2007-01-17 | Drug delivery treatment device |
Country Status (6)
Country | Link |
---|---|
US (2) | US9084662B2 (en) |
EP (2) | EP1978892B1 (en) |
JP (1) | JP5388582B2 (en) |
CA (1) | CA2637602C (en) |
ES (1) | ES2653845T3 (en) |
WO (1) | WO2007084582A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2429607A1 (en) * | 2009-05-15 | 2012-03-21 | iScience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9066779B2 (en) | 2009-01-29 | 2015-06-30 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
EP3092983A1 (en) * | 2013-03-15 | 2016-11-16 | Abbott Medical Optics Inc. | Trans-sclera portal for delivery of therapeutic agents |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
US9851351B2 (en) | 2009-01-29 | 2017-12-26 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9861521B2 (en) | 2010-08-05 | 2018-01-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US9883968B2 (en) | 2011-09-16 | 2018-02-06 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US9895369B2 (en) | 2014-08-08 | 2018-02-20 | Forsight Vision4, Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CN107809977A (en) * | 2015-06-24 | 2018-03-16 | 希里奥尼克斯公司 | For treating the Multiple-Aperture Device of dry type and the injectable of wet age-related macular denaturation or diabetic retinopathy |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10398593B2 (en) | 2013-03-28 | 2019-09-03 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US10874548B2 (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11419759B2 (en) | 2017-11-21 | 2022-08-23 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
US11432959B2 (en) | 2015-11-20 | 2022-09-06 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
CA2683224C (en) | 2001-04-07 | 2014-12-02 | Glaukos Corporation | System and methods thereof for treatment of ocular disorders |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
US7951155B2 (en) * | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
ES2551782T3 (en) | 2006-01-17 | 2015-11-23 | Transcend Medical, Inc. | Device for the treatment of glaucoma |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US8758290B2 (en) | 2010-11-15 | 2014-06-24 | Aquesys, Inc. | Devices and methods for implanting a shunt in the suprachoroidal space |
US9173770B1 (en) * | 2007-06-05 | 2015-11-03 | Amad Tayebi | Punctal plugs for insertion into the tear ducts to slow drainage of eye moisture and methods for the manufacture thereof |
US8334008B1 (en) * | 2007-06-05 | 2012-12-18 | Amad Tayebi | Article for dispensing a medicinal ingredient and a method the manufacture thereof |
EP2173289A4 (en) | 2007-07-17 | 2010-11-24 | Transcend Medical Inc | Ocular implant with hydrogel expansion capabilities |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US8414646B2 (en) | 2007-12-27 | 2013-04-09 | Forsight Labs, Llc | Intraocular, accommodating lens and methods of use |
EP3381407A1 (en) | 2008-01-03 | 2018-10-03 | Forsight Labs, Llc | Intraocular, accomodating lens and methods of use |
EP2676701B1 (en) | 2008-01-07 | 2016-03-30 | Salutaris Medical Devices, Inc. | Devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
US8267882B2 (en) | 2008-03-05 | 2012-09-18 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
ES2786101T3 (en) | 2009-01-28 | 2020-10-08 | Alcon Inc | Ocular implant with qualities of rigidity, methods and implantation system |
US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
US20100233241A1 (en) * | 2009-03-13 | 2010-09-16 | Vista Scientific Llc | Ophthalmic drug delivery system and applications |
EP2408409B8 (en) * | 2009-03-16 | 2016-06-08 | Endoshape, Inc. | Reliably retained shape memory ophthal-mological implants |
US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
EP2520233B1 (en) | 2009-04-02 | 2017-11-01 | Endoshape, Inc. | Vascular occlusion devices |
WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
CA2766192C (en) | 2009-07-09 | 2017-10-24 | Ivantis, Inc. | Ocular implants for residing partially in schlemm's canal |
US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US8535333B2 (en) | 2009-07-29 | 2013-09-17 | Transcend Medical, Inc. | Ocular implant applier and methods of use |
JP5856569B2 (en) | 2010-02-05 | 2016-02-10 | サイト サイエンシーズ, インコーポレイテッド | Device for reducing intraocular pressure and kit including the same |
PL2600812T3 (en) | 2010-08-05 | 2022-01-24 | Forsight Vision4, Inc. | Apparatus to treat an eye |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
WO2013040079A1 (en) | 2011-09-13 | 2013-03-21 | Dose Medical Corporation | Intraocular physiological sensor |
WO2014160320A2 (en) | 2013-03-13 | 2014-10-02 | Endoshape Inc. | Continuous embolic coil and methods and devices for delivery of the same |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
EP2804542B1 (en) | 2012-01-17 | 2017-03-01 | Endoshape, Inc. | Occlusion device for a vascular or biological lumen |
US9855167B2 (en) | 2012-03-20 | 2018-01-02 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
CA2890471C (en) | 2012-11-08 | 2021-07-27 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
WO2014078288A1 (en) | 2012-11-14 | 2014-05-22 | Transcend Medical, Inc. | Flow promoting ocular implant |
WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
EP3003454B1 (en) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Apparatus for drug delivery using multiple reservoirs |
EP3068354B1 (en) | 2013-11-14 | 2023-06-28 | Aquesys, Inc. | Intraocular shunt inserter |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
CA2952958A1 (en) | 2014-06-20 | 2015-12-23 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
EP3370644A1 (en) | 2015-09-22 | 2018-09-12 | Novartis AG | Ocular implant container |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
TW201722377A (en) * | 2015-12-16 | 2017-07-01 | 諾華公司 | Devices and methods for a cannula-delivered treatment material application device |
WO2017139375A1 (en) | 2016-02-10 | 2017-08-17 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
JP2019514581A (en) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル,インコーポレイテッド | Systems and methods for ocular drug delivery |
USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
CN110177527B (en) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | Device and method for adjusting insertion depth of needle for medicament delivery |
USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
TWI797136B (en) | 2017-06-16 | 2023-04-01 | 美商亞斯庫拉科技公司 | Thermoresponsive polymers and uses thereof |
JP6990321B2 (en) * | 2018-02-22 | 2022-01-12 | イバンティス インコーポレイテッド | Ocular implants and delivery system |
BR112021026265A2 (en) | 2019-06-27 | 2022-06-14 | Layerbio Inc | Eye device delivery methods and systems |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US20210220175A1 (en) * | 2020-01-17 | 2021-07-22 | Quest Medical, Inc. | Nasolacrimal Duct Stent Assembly and Method |
EP4274529A1 (en) | 2021-01-11 | 2023-11-15 | Alcon Inc. | Systems and methods for viscoelastic delivery |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5601094A (en) | 1994-11-22 | 1997-02-11 | Reiss; George R. | Ophthalmic shunt |
US6102045A (en) | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20020133168A1 (en) | 2001-03-16 | 2002-09-19 | Smedley Gregory T. | Applicator and methods for placing a trabecular shunt for glaucoma treatment |
US20020143284A1 (en) | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US20020156413A1 (en) | 1999-04-27 | 2002-10-24 | Stuart K. Williams | Glaucoma shunt and a method of making and surgically implanting the same |
US20020165478A1 (en) | 2001-05-02 | 2002-11-07 | Morteza Gharib | Bifurcatable trabecular shunt for glaucoma treatment |
US20020188282A1 (en) | 2001-02-13 | 2002-12-12 | Robert Greenberg | Implantable drug delivery device |
US20020193725A1 (en) | 2000-02-24 | 2002-12-19 | Odrich Steven A. | Injectable glaucoma device |
US6508779B1 (en) | 1995-05-05 | 2003-01-21 | John Suson | Adjustable flow rate glaucoma shunt and method of using same |
US6544208B2 (en) | 2000-12-29 | 2003-04-08 | C. Ross Ethier | Implantable shunt device |
US20030236483A1 (en) | 2002-06-25 | 2003-12-25 | Ren David H | Dual drainage ocular shunt for glaucoma |
US20040015140A1 (en) | 2002-07-19 | 2004-01-22 | Shields Milton B. | Uveoscleral drainage device |
US20040102729A1 (en) | 2002-04-08 | 2004-05-27 | David Haffner | Devices and methods for glaucoma treatment |
WO2004066871A2 (en) | 2003-01-24 | 2004-08-12 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US6827700B2 (en) | 1999-04-26 | 2004-12-07 | Gmp Vision Solutions, Inc. | Shunt device and method for treating glaucoma |
US20040254521A1 (en) | 2003-06-16 | 2004-12-16 | Solx, Inc. | Shunt for the treatment of glaucoma |
US20050107734A1 (en) | 2003-11-14 | 2005-05-19 | Coroneo Minas T. | Ocular pressure regulation |
WO2006014434A2 (en) | 2004-07-02 | 2006-02-09 | Eliot Lazar | Treatment medium delivery device and methods for delivery |
Family Cites Families (223)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS152018B1 (en) | 1970-05-27 | 1973-12-19 | ||
US3915172A (en) | 1970-05-27 | 1975-10-28 | Ceskoslovenska Akademie Ved | Capillary drain for glaucoma |
US3788327A (en) | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4037604A (en) | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4402681A (en) | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
GB2101891A (en) | 1981-07-18 | 1983-01-26 | Anthony Christopher Be Molteno | Device for draining aqueous humour |
US4457757A (en) | 1981-07-20 | 1984-07-03 | Molteno Anthony C B | Device for draining aqueous humour |
US4554918A (en) | 1982-07-28 | 1985-11-26 | White Thomas C | Ocular pressure relief device |
US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4787885A (en) | 1984-04-06 | 1988-11-29 | Binder Perry S | Hydrogel seton |
US4634418A (en) | 1984-04-06 | 1987-01-06 | Binder Perry S | Hydrogel seton |
US4604087A (en) | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
EP0228185B1 (en) | 1985-11-27 | 1990-07-25 | Thomas C. White | Tissue-implantable fluid-dissipating device |
NZ215409A (en) | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4722724A (en) | 1986-06-23 | 1988-02-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4826478A (en) | 1986-06-23 | 1989-05-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US4846172A (en) | 1987-05-26 | 1989-07-11 | Berlin Michael S | Laser-delivery eye-treatment method |
US4900300A (en) | 1987-07-06 | 1990-02-13 | Lee David A | Surgical instrument |
US4886488A (en) | 1987-08-06 | 1989-12-12 | White Thomas C | Glaucoma drainage the lacrimal system and method |
AU2308988A (en) | 1987-08-06 | 1989-03-01 | Thomas C. White | Glaucoma drainage in the lacrimal system |
US4782820A (en) | 1987-10-22 | 1988-11-08 | Woods Randall L | Iris retaining device |
US4936825A (en) | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
US4932966A (en) | 1988-08-15 | 1990-06-12 | Storz Instrument Company | Accommodating intraocular lens |
US5071408A (en) | 1988-10-07 | 1991-12-10 | Ahmed Abdul Mateen | Medical valve |
US4957505A (en) | 1989-11-03 | 1990-09-18 | Mcdonald Henry H | Cannulated spring forceps for intra-ocular lens implantation method |
US4946436A (en) | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US4968296A (en) | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5092837A (en) | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
US5073163A (en) | 1990-01-29 | 1991-12-17 | Lippman Myron E | Apparatus for treating glaucoma |
SE9000491L (en) | 1990-02-12 | 1991-08-13 | Atos Medical Ab | GLAUCOMA VALVE |
US5180362A (en) | 1990-04-03 | 1993-01-19 | Worst J G F | Gonio seton |
RU2056818C1 (en) | 1990-04-28 | 1996-03-27 | Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Device for strengthening erection |
US5041081A (en) | 1990-05-18 | 1991-08-20 | Odrich Ronald B | Ocular implant for controlling glaucoma |
US5127901A (en) | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5476445A (en) | 1990-05-31 | 1995-12-19 | Iovision, Inc. | Glaucoma implant with a temporary flow restricting seal |
US5178604A (en) | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5397300A (en) | 1990-05-31 | 1995-03-14 | Iovision, Inc. | Glaucoma implant |
US6007511A (en) | 1991-05-08 | 1999-12-28 | Prywes; Arnold S. | Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation |
US5300020A (en) | 1991-05-31 | 1994-04-05 | Medflex Corporation | Surgically implantable device for glaucoma relief |
US5171213A (en) | 1991-08-14 | 1992-12-15 | Price Jr Francis W | Technique for fistulization of the eye and an eye filtration prosthesis useful therefor |
US5326345A (en) | 1991-08-14 | 1994-07-05 | Price Jr Francis W | Eye filtration prostheses |
US5346464A (en) | 1992-03-10 | 1994-09-13 | Camras Carl B | Method and apparatus for reducing intraocular pressure |
RU2018289C1 (en) | 1992-03-19 | 1994-08-30 | Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Method of treatment of secondary glaucoma in children |
US5370607A (en) | 1992-10-28 | 1994-12-06 | Annuit Coeptis, Inc. | Glaucoma implant device and method for implanting same |
WO1994013234A1 (en) | 1992-12-17 | 1994-06-23 | Michael Andrew Coote | Implant device and method for treatment of glaucoma |
US5338291A (en) | 1993-02-03 | 1994-08-16 | Pudenz-Schulte Medical Research Corporation | Glaucoma shunt and method for draining aqueous humor |
US5342370A (en) | 1993-03-19 | 1994-08-30 | University Of Miami | Method and apparatus for implanting an artifical meshwork in glaucoma surgery |
FR2710269A1 (en) | 1993-09-22 | 1995-03-31 | Voir Vivre | Implantable device for the treatment of edemas. |
US5676944A (en) | 1993-10-06 | 1997-10-14 | The Regents Of The University Of California | Ocular therapy with homologous macrophages |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5454746A (en) | 1994-01-06 | 1995-10-03 | Meccano, S.A. | Toy hand tool |
US5743868A (en) | 1994-02-14 | 1998-04-28 | Brown; Reay H. | Corneal pressure-regulating implant device |
IL109499A (en) | 1994-05-02 | 1998-01-04 | Univ Ramot | Implant device for draining excess intraocular fluid |
US5704907A (en) | 1994-07-22 | 1998-01-06 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
RU2074686C1 (en) | 1994-08-10 | 1997-03-10 | Волгоградский филиал Межотраслевого научно-технического комплекса "Микрохирургия глаза" | Method to treat glaucoma |
RU2074687C1 (en) | 1994-08-10 | 1997-03-10 | Волгоградский филиал Межотраслевого научно-технического комплекса "Микрохирургия глаза" | Method to treat glaucoma |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5569197A (en) | 1994-12-21 | 1996-10-29 | Schneider (Usa) Inc | Drug delivery guidewire |
US5433701A (en) | 1994-12-21 | 1995-07-18 | Rubinstein; Mark H. | Apparatus for reducing ocular pressure |
US5558630A (en) | 1994-12-30 | 1996-09-24 | Fisher; Bret L. | Intrascleral implant and method for the regulation of intraocular pressure |
WO1996020742A1 (en) * | 1995-01-06 | 1996-07-11 | Wong Vernon G | Improve eye implant for relief of glaucoma |
AU5857396A (en) | 1995-05-14 | 1996-11-29 | Optonol Ltd. | Intraocular implant, delivery device, and method of implanta tion |
IL113723A (en) | 1995-05-14 | 2002-11-10 | Optonol Ltd | Intraocular implant |
US5968058A (en) | 1996-03-27 | 1999-10-19 | Optonol Ltd. | Device for and method of implanting an intraocular implant |
US5758562A (en) | 1995-10-11 | 1998-06-02 | Schneider (Usa) Inc. | Process for manufacturing braided composite prosthesis |
US5741292A (en) | 1995-10-26 | 1998-04-21 | Eagle Vision | Punctum dilating and plug inserting instrument with push-button plug release |
US20040148022A1 (en) | 1996-03-18 | 2004-07-29 | Eggleston Harry C. | Modular intraocular implant |
US5807302A (en) | 1996-04-01 | 1998-09-15 | Wandel; Thaddeus | Treatment of glaucoma |
US6007510A (en) | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
US6881197B1 (en) | 1996-10-25 | 2005-04-19 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
US6142969A (en) | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
AUPO394496A0 (en) | 1996-11-29 | 1997-01-02 | Lions Eye Institute | Biological microfistula tube and implantation method and apparatus |
US6261256B1 (en) | 1996-12-20 | 2001-07-17 | Abdul Mateen Ahmed | Pocket medical valve & method |
US5713844A (en) | 1997-01-10 | 1998-02-03 | Peyman; Gholam A. | Device and method for regulating intraocular pressure |
GB9700390D0 (en) | 1997-01-10 | 1997-02-26 | Biocompatibles Ltd | Device for use in the eye |
FR2759577B1 (en) | 1997-02-17 | 1999-08-06 | Corneal Ind | DEEP SCLERECTOMY IMPLANT |
US5893837A (en) | 1997-02-28 | 1999-04-13 | Staar Surgical Company, Inc. | Glaucoma drain implanting device and method |
US5882327A (en) | 1997-04-17 | 1999-03-16 | Jacob; Jean T. | Long-term glaucoma drainage implant |
US6050970A (en) | 1997-05-08 | 2000-04-18 | Pharmacia & Upjohn Company | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye |
US5752928A (en) | 1997-07-14 | 1998-05-19 | Rdo Medical, Inc. | Glaucoma pressure regulator |
US6306426B1 (en) | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
EP0898947A3 (en) | 1997-08-15 | 1999-09-08 | GRIESHABER & CO. AG SCHAFFHAUSEN | Method and apparatus to improve the outflow of the aqueous humor of an eye |
US8313454B2 (en) | 1997-11-20 | 2012-11-20 | Optonol Ltd. | Fluid drainage device, delivery device, and associated methods of use and manufacture |
US6203513B1 (en) | 1997-11-20 | 2001-03-20 | Optonol Ltd. | Flow regulating implant, method of manufacture, and delivery device |
US6077299A (en) | 1998-06-22 | 2000-06-20 | Eyetronic, Llc | Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma |
US6264668B1 (en) | 1998-09-16 | 2001-07-24 | Arnold S. Prywes | Ophthalmologic instrument for producing a fistula in the sclera |
JP3316748B2 (en) | 1998-10-20 | 2002-08-19 | 株式会社村田製作所 | Electroless plating holder and electroless plating method |
FR2790173A1 (en) | 1999-02-24 | 2000-08-25 | Canon Kk | DIGITAL SIGNAL TRANSFORMATION DEVICE AND METHOD |
US20050119601A9 (en) | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US6558342B1 (en) | 1999-06-02 | 2003-05-06 | Optonol Ltd. | Flow control device, introducer and method of implanting |
US6221078B1 (en) | 1999-06-25 | 2001-04-24 | Stephen S. Bylsma | Surgical implantation apparatus |
DK1239774T3 (en) | 1999-12-10 | 2006-01-16 | Iscience Corp | Apparatus for the treatment of eye diseases |
RU2157678C1 (en) | 1999-12-22 | 2000-10-20 | Макашова Надежда Васильевна | Surgical method for treating the cases of glaucoma |
AU2626401A (en) | 2000-01-03 | 2001-07-16 | Johns Hopkins University, The | Surgical devices and methods of use thereof for enhanced tactile perception |
US20050119737A1 (en) | 2000-01-12 | 2005-06-02 | Bene Eric A. | Ocular implant and methods for making and using same |
US6589203B1 (en) | 2000-01-26 | 2003-07-08 | Peter Mitrev | Glaucoma drainage device implant |
US6375642B1 (en) | 2000-02-15 | 2002-04-23 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving a drainage of aqueous humor within the eye |
US20050277864A1 (en) | 2000-04-14 | 2005-12-15 | David Haffner | Injectable gel implant for glaucoma treatment |
US20030060752A1 (en) | 2000-04-14 | 2003-03-27 | Olav Bergheim | Glaucoma device and methods thereof |
US6533768B1 (en) * | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US20040111050A1 (en) | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
US20050049578A1 (en) | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US9820883B2 (en) | 2000-05-19 | 2017-11-21 | Michael S. Berlin | Method for treating glaucoma |
JP2003535646A (en) | 2000-06-19 | 2003-12-02 | グローコス コーポレーション | Trabecular shunt with stent mounted and method therefor |
US7462194B1 (en) | 2000-08-04 | 2008-12-09 | Blake Larry W | Two part “L”-shaped phakic IOL |
US6699211B2 (en) | 2000-08-22 | 2004-03-02 | James A. Savage | Method and apparatus for treatment of glaucoma |
DE10042310A1 (en) | 2000-08-29 | 2002-03-14 | Aixmed Ges Fuer Medizintechnik | Aqueous humor drainage device |
ES2312456T3 (en) | 2000-08-30 | 2009-03-01 | Johns Hopkins University | DEVICES FOR INTRAOCULAR SUPPLY OF PHARMACOS. |
FR2813521B1 (en) | 2000-09-01 | 2003-06-13 | Ioltechnologie Production | GLAUCOME DRAIN |
US6730056B1 (en) | 2000-09-21 | 2004-05-04 | Motorola, Inc. | Eye implant for treating glaucoma and method for manufacturing same |
US6962573B1 (en) | 2000-10-18 | 2005-11-08 | Wilcox Michael J | C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use |
WO2002036052A1 (en) | 2000-11-01 | 2002-05-10 | Glaukos Corporation | Glaucoma treatment device |
US6592621B1 (en) | 2000-11-10 | 2003-07-15 | Rudolph S. Domino | Flexible intra-ocular lens of variable focus |
US6595945B2 (en) | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
US6881198B2 (en) | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
MXPA03006394A (en) | 2001-01-18 | 2003-10-15 | Univ California | Minimally invasive glaucoma surgical instrument and method. |
US6989007B2 (en) | 2001-02-21 | 2006-01-24 | Solx, Inc. | Devices and techniques for treating glaucoma |
JP2002263124A (en) | 2001-03-12 | 2002-09-17 | Masashige Nakayama | Eye disease treating method for animal and artificial lachrymal duct used therefor |
US20030028228A1 (en) | 2001-03-30 | 2003-02-06 | Sand Bruce J. | Treatment of collagen |
US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
CA2683224C (en) | 2001-04-07 | 2014-12-02 | Glaukos Corporation | System and methods thereof for treatment of ocular disorders |
US7488303B1 (en) | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
AT409586B (en) | 2001-04-26 | 2002-09-25 | Clemens Dr Vass | Implant draining aqueous humor from anterior chamber of eye into Schlemm's channel, includes fixation plate for stabilization on sclera |
AU2002347269A1 (en) | 2001-05-01 | 2003-01-02 | Glaukos Corporation | Glaucoma device and methods thereof |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
WO2002089699A2 (en) | 2001-05-03 | 2002-11-14 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US6638305B2 (en) | 2001-05-15 | 2003-10-28 | Advanced Medical Optics, Inc. | Monofocal intraocular lens convertible to multifocal intraocular lens |
EP2316394B1 (en) * | 2001-06-12 | 2016-11-23 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
US7118597B2 (en) | 2001-06-22 | 2006-10-10 | David Miller | Accommodating intraocular lens |
EP1399097A4 (en) | 2001-06-22 | 2005-04-27 | David Miller | An improved accommodating intraocular lens |
US7031776B2 (en) | 2001-06-29 | 2006-04-18 | Optobionics | Methods for improving damaged retinal cell function |
US6648283B2 (en) | 2001-07-06 | 2003-11-18 | Joanne M. Chase | Adjustable ornament display apparatus |
EP1418864A4 (en) | 2001-08-03 | 2009-07-01 | Research Technologies Glaucoma | Method and intra sclera implant for treatment of glaucoma and presbyopia |
BR0211969A (en) | 2001-08-16 | 2006-11-07 | Gmp Vision Solutions Inc | improved bypass device and its deployment method |
US6443985B1 (en) | 2001-08-27 | 2002-09-03 | Randall Woods | Intraocular lens implant having eye accommodating capabilities |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
JP2005501602A (en) | 2001-08-29 | 2005-01-20 | カルバーリョ、リカルド エイ.ピー. デ | Sealable implantable device for unidirectional delivery of therapeutic agents to tissue |
US20030097151A1 (en) | 2001-10-25 | 2003-05-22 | Smedley Gregory T. | Apparatus and mitochondrial treatment for glaucoma |
US20070123982A1 (en) | 2001-11-06 | 2007-05-31 | Judith Yablonski | Intra-ocular lens |
US7163543B2 (en) | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030093084A1 (en) | 2001-11-13 | 2003-05-15 | Optonol Ltd. | Delivery devices for flow regulating implants |
US6712843B2 (en) | 2001-11-20 | 2004-03-30 | Scimed Life Systems, Inc | Stent with differential lengthening/shortening members |
WO2003045285A1 (en) | 2001-11-30 | 2003-06-05 | Medicel Ag | Kit for implanting an intra-ocular lens |
US7097660B2 (en) | 2001-12-10 | 2006-08-29 | Valdemar Portney | Accommodating intraocular lens |
US6966888B2 (en) | 2002-01-13 | 2005-11-22 | Eagle Vision, Inc. | Sinus valved glaucoma shunt |
FR2835424B1 (en) | 2002-02-01 | 2004-11-26 | Khalil Hanna | ACCOMODATIVE INTRACAPSULAR IMPLANT |
WO2003073968A2 (en) | 2002-02-28 | 2003-09-12 | Gmp Vision Solutions, Inc. | Device and method for monitoring aqueous flow within the eye |
US20060200113A1 (en) | 2002-03-07 | 2006-09-07 | David Haffner | Liquid jet for glaucoma treatment |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030229303A1 (en) | 2002-03-22 | 2003-12-11 | Haffner David S. | Expandable glaucoma implant and methods of use |
US20040147870A1 (en) | 2002-04-08 | 2004-07-29 | Burns Thomas W. | Glaucoma treatment kit |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US20040024345A1 (en) | 2002-04-19 | 2004-02-05 | Morteza Gharib | Glaucoma implant with valveless flow bias |
WO2003099175A1 (en) | 2002-05-29 | 2003-12-04 | University Of Saskatchewan Technologies Inc. | A shunt and method treatment of glaucoma |
DE60325615D1 (en) | 2002-08-08 | 2009-02-12 | Glaukos Corp | IMPLANTABLE OXULAR PUMP FOR REDUCING EYE REMINDER |
US7192412B1 (en) | 2002-09-14 | 2007-03-20 | Glaukos Corporation | Targeted stent placement and multi-stent therapy |
US7699882B2 (en) | 2002-09-17 | 2010-04-20 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
TWI282271B (en) | 2002-09-18 | 2007-06-11 | Allergan Inc | Apparatus for delivery of ocular implants |
US7317777B2 (en) * | 2002-10-07 | 2008-01-08 | International Business Machines Corporation | Digital adaptive control loop for data deserialization |
US20040082993A1 (en) | 2002-10-25 | 2004-04-29 | Randall Woods | Capsular intraocular lens implant having a refractive liquid therein |
US20040082995A1 (en) | 2002-10-25 | 2004-04-29 | Randall Woods | Telescopic intraocular lens implant for treating age-related macular degeneration |
AU2003291377A1 (en) | 2002-11-06 | 2004-06-03 | Gmp Vision Solutions, Inc. | Storage apparatus for surgical implant device |
US7381221B2 (en) | 2002-11-08 | 2008-06-03 | Advanced Medical Optics, Inc. | Multi-zonal monofocal intraocular lens for correcting optical aberrations |
WO2004053568A1 (en) | 2002-12-06 | 2004-06-24 | Visx, Incorporated | Presbyopia correction using patient data |
US7320517B2 (en) | 2002-12-06 | 2008-01-22 | Visx, Incorporated | Compound modulation transfer function for laser surgery and other optical applications |
US7160264B2 (en) | 2002-12-19 | 2007-01-09 | Medtronic-Xomed, Inc. | Article and method for ocular aqueous drainage |
JP2004208898A (en) | 2002-12-27 | 2004-07-29 | Japan Science & Technology Agency | Hydatoid discharging implant for glaucoma treatment |
WO2004062469A2 (en) | 2003-01-13 | 2004-07-29 | Clarity Corporation | Sinus valved glaucoma shunt |
US20040216749A1 (en) | 2003-01-23 | 2004-11-04 | Hosheng Tu | Vasomodulation during glaucoma surgery |
CA2515568A1 (en) | 2003-02-18 | 2004-09-02 | Hampar Karageozian | Methods and devices for draining fluids and lowering intraocular pressure |
WO2005105197A2 (en) | 2003-02-28 | 2005-11-10 | Gmp Vision Solutions, Inc. | Indwelling shunt device and methods for treating glaucoma |
US20040193095A1 (en) | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20040193262A1 (en) | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US7341599B1 (en) | 2003-04-09 | 2008-03-11 | Minu, Llc | Intraocular lens for correcting presbyopia |
US8404269B2 (en) | 2003-04-11 | 2013-03-26 | Michael Snyder | Sustained release implantable eye device |
DE602004028638D1 (en) * | 2003-05-02 | 2010-09-23 | Surmodics Inc | System for the controlled release of a bioactive agent in the back of the eye |
US20040236343A1 (en) | 2003-05-23 | 2004-11-25 | Taylor Jon B. | Insertion tool for ocular implant and method for using same |
US20040237971A1 (en) | 2003-06-02 | 2004-12-02 | Hema Radhakrishnan | Methods and apparatuses for controlling optical aberrations to alter modulation transfer functions |
CA2528060C (en) | 2003-06-10 | 2012-12-11 | Neomedix Corporation | Device and methods useable for treatment of glaucoma and other surgical procedures |
US20060069340A1 (en) | 2003-06-16 | 2006-03-30 | Solx, Inc. | Shunt for the treatment of glaucoma |
US20050181018A1 (en) | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
US20050090506A1 (en) * | 2003-10-24 | 2005-04-28 | Nippon Soda Co., Ltd. | Insecticidal perfluoroalkylthiazole derivatives |
WO2005046516A2 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and anti-scarring agents |
EP1689333B1 (en) | 2003-12-05 | 2014-02-12 | Innfocus, Inc. | Improved glaucoma implant device |
CN1909859B (en) | 2004-01-23 | 2010-05-12 | 伊萨恩斯外科手术股份有限公司 | Composite ophthalmic microcannula |
US20050250788A1 (en) | 2004-01-30 | 2005-11-10 | Hosheng Tu | Aqueous outflow enhancement with vasodilated aqueous cavity |
US20060036207A1 (en) | 2004-02-24 | 2006-02-16 | Koonmen James P | System and method for treating glaucoma |
US7364564B2 (en) | 2004-03-02 | 2008-04-29 | Becton, Dickinson And Company | Implant having MEMS flow module with movable, flow-controlling baffle |
DE502004009370D1 (en) | 2004-02-27 | 2009-05-28 | Advanced Vision Science Inc | LENS RECEPTION FOR A DEVICE FOR INSERTING DEFORMABLE INTRAOCULAR LENSES |
NL1025622C2 (en) | 2004-03-03 | 2005-09-07 | Accolens Internat B V | Two optical elements with variable optical power together forming a lens for use as an intraocular lens. |
US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
ES2349954T3 (en) | 2004-04-22 | 2011-01-13 | Advanced Vision Science, Inc. | DEVICE FOR THE IMPLEMENTATION OF DEFORMABLE INTRAOCULAR LENSES. |
CN1976732A (en) | 2004-04-29 | 2007-06-06 | i科学外科公司 | Apparatus and method for surgical enhancement of aqueous humor drainage |
AU2005240073A1 (en) * | 2004-04-29 | 2005-11-17 | Iscience Surgical Corporation | Apparatus and method for ocular treatment |
US20050244462A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US9713527B2 (en) | 2004-04-30 | 2017-07-25 | Rxsight, Inc. | Multilens intraocular lens system with injectable accommodation material |
US7357778B2 (en) | 2004-05-20 | 2008-04-15 | Ajay Bhalla | Aqueous drainage and flow regulating implant |
US20050267398A1 (en) | 2004-05-27 | 2005-12-01 | Dimitri Protopsaltis | Glaucoma shunt |
WO2005122980A1 (en) | 2004-06-10 | 2005-12-29 | James Savage | Apparatus and method for non-pharmacological treatment of glaucoma and lowering intraocular pressure |
US7862531B2 (en) | 2004-06-25 | 2011-01-04 | Optonol Ltd. | Flow regulating implants |
US7717875B2 (en) | 2004-07-20 | 2010-05-18 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Steerable catheter with hydraulic or pneumatic actuator |
US7117870B2 (en) | 2004-07-26 | 2006-10-10 | Clarity Corporation | Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same |
US20060032507A1 (en) | 2004-08-11 | 2006-02-16 | Hosheng Tu | Contrast-enhanced ocular imaging |
US20060173397A1 (en) | 2004-11-23 | 2006-08-03 | Hosheng Tu | Ophthalmology implants and methods of manufacture |
US20060129215A1 (en) | 2004-12-09 | 2006-06-15 | Helmus Michael N | Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery |
WO2007035895A2 (en) | 2005-09-21 | 2007-03-29 | Cook Incorporated | Endoluminal stent graft delivery assembly |
WO2007041593A2 (en) | 2005-10-03 | 2007-04-12 | Combinatorx, Incorporated | Anti-scarring drug combinations and use thereof |
US20070141106A1 (en) | 2005-10-19 | 2007-06-21 | Bonutti Peter M | Drug eluting implant |
ES2653845T3 (en) | 2006-01-17 | 2018-02-09 | Novartis Ag | Drug administration treatment device |
ES2551782T3 (en) | 2006-01-17 | 2015-11-23 | Transcend Medical, Inc. | Device for the treatment of glaucoma |
US8585753B2 (en) | 2006-03-04 | 2013-11-19 | John James Scanlon | Fibrillated biodegradable prosthesis |
CN103393483B (en) | 2006-03-31 | 2016-08-24 | 玛提治疗有限公司 | Medicine release method, structure and composition for nose tear system |
US9610153B2 (en) | 2006-04-03 | 2017-04-04 | Isaac Lipshitz | Intra-ocular implant |
US20070293807A1 (en) | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
GB0618262D0 (en) | 2006-09-16 | 2006-10-25 | Khoury Elie | Accommodative intra-ocular lens |
EP2088976B1 (en) | 2006-11-10 | 2019-07-03 | Glaukos Corporation | Uveoscleral shunt |
EP1932492B1 (en) | 2006-12-13 | 2011-09-14 | Akkolens International B.V. | Accommodating intraocular lens with variable correction |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
-
2007
- 2007-01-17 ES ES07718113.9T patent/ES2653845T3/en active Active
- 2007-01-17 WO PCT/US2007/001269 patent/WO2007084582A2/en active Application Filing
- 2007-01-17 JP JP2008551364A patent/JP5388582B2/en active Active
- 2007-01-17 CA CA2637602A patent/CA2637602C/en not_active Expired - Fee Related
- 2007-01-17 US US11/624,168 patent/US9084662B2/en active Active
- 2007-01-17 EP EP07718113.9A patent/EP1978892B1/en active Active
- 2007-01-17 EP EP17201248.6A patent/EP3338743A1/en not_active Withdrawn
-
2015
- 2015-07-20 US US14/804,008 patent/US9668917B2/en active Active
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6102045A (en) | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US5601094A (en) | 1994-11-22 | 1997-02-11 | Reiss; George R. | Ophthalmic shunt |
US6508779B1 (en) | 1995-05-05 | 2003-01-21 | John Suson | Adjustable flow rate glaucoma shunt and method of using same |
US20040260228A1 (en) | 1999-04-26 | 2004-12-23 | Lynch Mary G. | Stent device and method for treating glaucoma |
US6827700B2 (en) | 1999-04-26 | 2004-12-07 | Gmp Vision Solutions, Inc. | Shunt device and method for treating glaucoma |
US20020156413A1 (en) | 1999-04-27 | 2002-10-24 | Stuart K. Williams | Glaucoma shunt and a method of making and surgically implanting the same |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20020193725A1 (en) | 2000-02-24 | 2002-12-19 | Odrich Steven A. | Injectable glaucoma device |
US6544208B2 (en) | 2000-12-29 | 2003-04-08 | C. Ross Ethier | Implantable shunt device |
US20020188282A1 (en) | 2001-02-13 | 2002-12-12 | Robert Greenberg | Implantable drug delivery device |
US20020133168A1 (en) | 2001-03-16 | 2002-09-19 | Smedley Gregory T. | Applicator and methods for placing a trabecular shunt for glaucoma treatment |
US20020143284A1 (en) | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US20020165478A1 (en) | 2001-05-02 | 2002-11-07 | Morteza Gharib | Bifurcatable trabecular shunt for glaucoma treatment |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US20040102729A1 (en) | 2002-04-08 | 2004-05-27 | David Haffner | Devices and methods for glaucoma treatment |
US20030236483A1 (en) | 2002-06-25 | 2003-12-25 | Ren David H | Dual drainage ocular shunt for glaucoma |
US20040015140A1 (en) | 2002-07-19 | 2004-01-22 | Shields Milton B. | Uveoscleral drainage device |
WO2004066871A2 (en) | 2003-01-24 | 2004-08-12 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US20040254521A1 (en) | 2003-06-16 | 2004-12-16 | Solx, Inc. | Shunt for the treatment of glaucoma |
US20050107734A1 (en) | 2003-11-14 | 2005-05-19 | Coroneo Minas T. | Ocular pressure regulation |
WO2006014434A2 (en) | 2004-07-02 | 2006-02-09 | Eliot Lazar | Treatment medium delivery device and methods for delivery |
Non-Patent Citations (3)
Title |
---|
"The Merck Index", 1998, MERCK & CO. |
GOODMAN; GILMAN: "The Pharmacological Basis of Therapeutics", MACMILLAN COMPANY |
See also references of EP1978892A4 |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9668917B2 (en) | 2006-01-17 | 2017-06-06 | Novartis Ag | Drug delivery treatment device |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9066779B2 (en) | 2009-01-29 | 2015-06-30 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10813788B2 (en) | 2009-01-29 | 2020-10-27 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9851351B2 (en) | 2009-01-29 | 2017-12-26 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US10656152B2 (en) | 2009-01-29 | 2020-05-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US11642310B2 (en) | 2009-01-29 | 2023-05-09 | Forsight Vision4, Inc. | Posterior segment drug delivery |
EP2429607A1 (en) * | 2009-05-15 | 2012-03-21 | iScience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
EP2429607A4 (en) * | 2009-05-15 | 2014-01-08 | Iscience Interventional Corp | Methods and apparatus for sub-retinal catheterization |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US11426306B2 (en) | 2009-05-18 | 2022-08-30 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US9861521B2 (en) | 2010-08-05 | 2018-01-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US11786396B2 (en) | 2010-08-05 | 2023-10-17 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US11679027B2 (en) | 2010-08-05 | 2023-06-20 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US10265215B2 (en) | 2010-08-05 | 2019-04-23 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US11065151B2 (en) | 2010-11-19 | 2021-07-20 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10874548B2 (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US11813196B2 (en) | 2011-06-28 | 2023-11-14 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US9883968B2 (en) | 2011-09-16 | 2018-02-06 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US10653554B2 (en) | 2011-09-16 | 2020-05-19 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US10603209B2 (en) | 2012-02-03 | 2020-03-31 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9597227B2 (en) | 2013-03-15 | 2017-03-21 | Abbott Medical Optics Inc. | Trans-sclera portal for delivery of therapeutic agents |
US11253394B2 (en) | 2013-03-15 | 2022-02-22 | Dose Medical Corporation | Controlled drug delivery ocular implants and methods of using same |
EP3092983A1 (en) * | 2013-03-15 | 2016-11-16 | Abbott Medical Optics Inc. | Trans-sclera portal for delivery of therapeutic agents |
US11510810B2 (en) | 2013-03-28 | 2022-11-29 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10398593B2 (en) | 2013-03-28 | 2019-09-03 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11337853B2 (en) | 2014-07-15 | 2022-05-24 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10765677B2 (en) | 2014-08-08 | 2020-09-08 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10363255B2 (en) | 2014-08-08 | 2019-07-30 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9895369B2 (en) | 2014-08-08 | 2018-02-20 | Forsight Vision4, Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US11110001B2 (en) | 2014-11-10 | 2021-09-07 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
CN107809977A (en) * | 2015-06-24 | 2018-03-16 | 希里奥尼克斯公司 | For treating the Multiple-Aperture Device of dry type and the injectable of wet age-related macular denaturation or diabetic retinopathy |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11432959B2 (en) | 2015-11-20 | 2022-09-06 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11419759B2 (en) | 2017-11-21 | 2022-08-23 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
Also Published As
Publication number | Publication date |
---|---|
EP1978892B1 (en) | 2017-11-15 |
JP2009523545A (en) | 2009-06-25 |
EP1978892A4 (en) | 2015-12-02 |
EP1978892A2 (en) | 2008-10-15 |
WO2007084582A3 (en) | 2007-12-21 |
US9668917B2 (en) | 2017-06-06 |
US9084662B2 (en) | 2015-07-21 |
CA2637602A1 (en) | 2007-07-26 |
US20070233037A1 (en) | 2007-10-04 |
JP5388582B2 (en) | 2014-01-15 |
EP3338743A1 (en) | 2018-06-27 |
ES2653845T3 (en) | 2018-02-09 |
CA2637602C (en) | 2014-09-16 |
US20150320596A1 (en) | 2015-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9668917B2 (en) | Drug delivery treatment device | |
US11510810B2 (en) | Ophthalmic implant for delivering therapeutic substances | |
US10111776B2 (en) | Implantable intraocular drug delivery apparatus, system and method | |
US9549846B2 (en) | Drug delivery devices and methods | |
TWI507184B (en) | Composite lacrimal insert and related methods | |
US20140323995A1 (en) | Targeted Drug Delivery Devices and Methods | |
WO2015085234A1 (en) | Implantable therapeutic devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008551364 Country of ref document: JP Ref document number: 2637602 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2007718113 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007718113 Country of ref document: EP |